[A18-16] Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2018
Project no.:
A18-16
Commission:
Commission awarded on 28.02.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus when metformin combined with another oral glucose-lowering medicinal product or with basal insulin does not provide adequate glycaemic control
Depending on therapeutic indication and treatment goal: hint of lesser benefit than under the comparator therapy or added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-38 | Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.